CJC-1295 with tesamorelin: two GHRH analogues on the same receptor, no study that combined them, a thousandfold gap in half-life, and the units per draw.
"CJC-1295 and tesamorelin" turns up as a stack on vendor and clinic pages, usually alongside the better-known CJC-1295 and ipamorelin pairing. The two belong to one family: both are modified versions of growth-hormone-releasing hormone (GHRH) and both act on the same receptor in the pituitary. What separates them is regulatory standing and time. Tesamorelin is an approved drug with a label and a half-life of minutes; CJC-1295 with DAC is an unapproved research peptide that stays in the blood for about a week. This page counts what has been studied (sources opened 2026-10-26), sets out what the pairing would mean pharmacologically, and converts the circulating amounts into syringe units. It reports figures; it suggests none.
The single-compound records are on tesamorelin dosage and CJC-1295 dosage; the two set side by side as alternatives, rather than as a combination, are on the daily-versus-weekly comparison of the two.
The record, counted
| Search, 2026-10-26 |
Result |
| ClinicalTrials.gov, "CJC-1295 tesamorelin" |
0 studies |
| ClinicalTrials.gov, tesamorelin |
24 studies |
| ClinicalTrials.gov, CJC-1295 |
1 study (NCT00267527, terminated 2006, no results) |
| PubMed, CJC-1295 AND tesamorelin |
16 records: 7 reviews (2026), 9 anti-doping detection methods (2015–2026), 0 administration studies |
| PubMed, CJC-1295 |
35 records |
| DailyMed, CJC-1295 |
0 labels |
The 16 shared PubMed records are the clearest picture of where the two names meet. Half are laboratory papers from anti-doping science, where the two are measured together because both are GHRH analogues that a urine test has to catch. The rest are 2026 reviews of injectable peptides in sports, orthopaedic and sexual medicine that list them in the same table. None reports giving either one to a participant.
One receptor, two clocks
The best-known growth-hormone stacks pair a GHRH analogue with a growth-hormone secretagogue such as ipamorelin. The rationale is that the two act through different receptors — GHRH through its own receptor, ipamorelin through the ghrelin receptor — and Bowers reported in 1993 that a GHRP given with GHRH released growth hormone synergistically in humans, more than either alone (as recorded on this site's tesamorelin and sermorelin stack page). CJC-1295 with tesamorelin is not that kind of pair. Both are GHRH-receptor agonists, so the combination puts two agonists on one receptor. No study has asked whether a second agonist adds anything at that receptor; the same question for tesamorelin with sermorelin is set out on the tesamorelin and sermorelin stack page.
The difference between them is how long each lasts.
|
Tesamorelin |
CJC-1295 with DAC |
| What it is |
GHRH(1-44) with an N-terminal hexenoyl group |
GHRH(1-29) analogue with an albumin-binding Drug Affinity Complex |
|---|
| Molecular weight (PubChem) |
5,136 (CID 16137828) |
3,647.2 (CID 91971820) |
|---|
| Half-life |
8 min (EGRIFTA SV), 11 min (EGRIFTA WR) |
5.8–8.1 days (Teichman 2006) |
|---|
| Labelled or studied regimen |
1.4 mg (SV) or 1.28 mg (WR) daily; 2 mg daily in the pivotal trial |
30–60 mcg/kg once, then weekly or biweekly, in healthy adults |
|---|
| Approval |
FDA-approved 2010 for HIV-associated abdominal fat |
None; DailyMed 0 records |
|---|
Tesamorelin gives a short daily signal that is gone within an hour. CJC-1295 with DAC gives a signal that persists for days. The 2006 pulsatility study is the one piece of direct evidence on what that continuous signal does: a week after a single injection, the body's growth-hormone pulses kept their normal rhythm, but the floor between pulses rose 7.5-fold. A daily tesamorelin injection on top of that raised floor has never been measured. The no-DAC form sold as CJC-1295 (the same peptide as Mod GRF 1-29) clears in minutes like tesamorelin and has no human study at all; the distinction is set out on CJC-1295 DAC vs no DAC.
The amounts that circulate, and their scale
Vendor and clinic pages recorded on this site's dosage pages on 2026-09-18 state 1 to 2 mg of tesamorelin once daily, often five days on and two off, and 1 to 2 mg a week of CJC-1295 with DAC, once weekly or split into two injections; for the no-DAC form, 100 to 300 mcg one to three times a day. None of these figures comes from a study of the pair.
By mass the two sides are unequal. A labelled week of tesamorelin is 9.8 mg, and the pivotal trial's week was 14 mg. The weekly CJC-1295 figure is 1 to 2 mg. By molecule count the gap narrows slightly — a milligram of CJC-1295 holds about 1.41 times as many molecules as a milligram of tesamorelin — but tesamorelin still carries most of the mass of any such stack. Neither count says anything about effect.
Units per draw
Units on a U-100 syringe = milligrams ÷ concentration in mg/mL × 100. Research vials of both are labelled 5 mg and 10 mg.
| Amount |
5 mg/mL |
3.33 mg/mL |
2.5 mg/mL |
| 100 mcg (CJC-1295 no DAC) |
2 units |
3 units |
4 units |
| 300 mcg (CJC-1295 no DAC) |
6 |
9 |
12 |
| 1 mg (either) |
20 |
30 |
40 |
| 1.4 mg (tesamorelin, EGRIFTA SV figure) |
28 |
42 |
56 |
| 2 mg (either) |
40 |
60 |
80 |
Where the concentrations come from: 5 mg/mL is a 5 mg vial with 1 mL of water or a 10 mg vial with 2 mL; 3.33 mg/mL a 10 mg vial with 3 mL; 2.5 mg/mL a 5 mg vial with 2 mL. Because the two peptides are reconstituted in separate vials, the two draws are separate numbers; the table does not describe one combined syringe. At the labelled 1.4 mg a day, a 10 mg tesamorelin vial holds seven daily amounts and a 5 mg vial three; at 2 mg a week, a 5 mg CJC-1295 vial holds two and a half weekly amounts. The tesamorelin vial arithmetic and CJC-1295 calculator work any vial and volume, and the mixing figures for each are on tesamorelin reconstitution and CJC-1295 reconstitution.
Labels, warnings and sport
Only one half of the pair has a label. The EGRIFTA SV label (read 2026-10-26) lists injection-site reactions, elevated IGF-1, fluid retention, glucose intolerance or diabetes and hypersensitivity among its warnings, and names arthralgia, injection-site redness and itching, pain in an extremity, peripheral oedema and muscle pain as the reactions reported in more than 5% of patients. Several of those — IGF-1, fluid, glucose — are effects of more growth hormone, the effect a second GHRH agonist would add to. CJC-1295 has no label, and its two human studies were short. Both names sit in section S2.2.4 of the 2026 World Anti-Doping Agency Prohibited List, and anti-doping laboratories have published methods that detect both.
What is not established
No study has given the two together, in people or animals. Nothing is known about whether a second GHRH agonist adds to the first, about IGF-1 or glucose under the combination, or about mixing the two in one syringe. Tesamorelin's dosage was set for one population, adults with HIV-associated abdominal fat; CJC-1295's rests on two short studies in healthy adults. Medibact's tesamorelin guide and CJC-1295 guide cover the compounds. Decisions about administering anything belong with a clinician.
Sources and dates
Opened 2026-10-26: ClinicalTrials.gov v2 API searches for "CJC-1295 tesamorelin" (0), tesamorelin (24) and CJC-1295 (1), and record NCT00267527 (status, dates, design); PubMed searches through NCBI E-utilities for CJC-1295 AND tesamorelin (16 records, titles and publication types read) and CJC-1295 (35); abstracts of Teichman et al. 2006 (PMID 16352683) and Ionescu and Frohman 2006 (PMID 17018654); the EGRIFTA SV label on openFDA (effective 2026-07-29), sections 2 and 6; PubChem CIDs 16137828 and 91971820; DailyMed search for CJC-1295 (0). From this site's pages with their read dates: tesamorelin half-lives and the EGRIFTA WR figures (2026-10-03), vendor figures (2026-09-18), the 2026 Prohibited List sections (2026-10-11 and 2026-10-17). Molecule-count and unit arithmetic by this site. Corrections go to the contact page.
